Sulfonyl Hydrazone Derivatives Targeting Glutathione Reductase: A Potential Strategy for Redox Modulation in Cancer

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Glutathione reductase (GR) is crucial for maintaining cellular redox balance and is often overexpressed in cancer cells.
• This overexpression supports tumor cell survival by neutralizing reactive oxygen species and maintaining antioxidant defenses.

Purpose of the Study:

• To synthesize and evaluate novel sulfonyl hydrazone analogs as potential inhibitors of human glutathione reductase (hGR).
• To investigate the mechanism of action and anticancer potential of the most potent inhibitor identified.

Main Methods:

• Synthesis and characterization of sulfonyl hydrazone analogs.
• In vitro enzyme inhibition assays to determine IC50 values.
• In silico molecular docking studies to elucidate binding interactions.
• In vitro cytotoxicity assays against human cancer cell lines (MCF-7, A549, HeLa).

Main Results:

• A series of compounds were synthesized, with IC50 values for hGR inhibition ranging from 198.1 to 3013 nM.
• Compound 6a demonstrated the most potent hGR inhibition.
• In silico analysis showed compound 6a binds to the NADP+ binding site of hGR, interfering with electron transfer.
• Compound 6a exhibited cytotoxic effects against MCF-7, A549, and HeLa cells, with EC50 values in the micromolar to millimolar range.
• Compound 6a showed weak cytotoxicity, especially against MCF-7 cells, at millimolar concentrations.

Conclusions:

• Sulfonyl hydrazone analogs are effective inhibitors of hGR.
• Compound 6a is a potent hGR inhibitor with demonstrated anticancer activity.
• Enhancing the membrane permeability of compound 6a could improve its therapeutic potential as an anticancer drug candidate.